contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


pharma-equity-group-vagtskifte-og-organisationsaendring

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Equity Research Analyst

Philip Coombes

Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.

Pharma Equity Group

Pharma Equity Group: Vagtskifte og organisationsændring

Aktien faldt med 3,48% fredag.
Selskabet meddelte at selskabets nuv&#xe6;rende CEO Thomas K. Sels&#xf8; fratr&#xe6;der den 31 marts 2025 efter eget &#xf8;nske. I stedet tager Chrstian Henrik Tange over pr. 1. april 2025.
Thomas Sels&#xf8; vil stadigv&#xe6;k v&#xe6;re tilknyttet selskabet som konsulent.
Christian Henrik Tange har blandt andet gennem flere &#xe5;r v&#xe6;ret ansat som CFO og Investment Manager i investeringsselskabet Karolinska Development, der er b&#xf8;rsnoteret p&#xe5; Nasdaq i Stockholm. Han er en erfaren topleder med over 25 &#xe5;rs erfaring inden for finansiel transformation, corporate finance, kapitalfremskaffelse og M&amp;A p&#xe5; tv&#xe6;rs af PE-st&#xf8;ttede, VC-st&#xf8;ttede og b&#xf8;rsnoterede selskaber i Europa og USA. Christian har evne til at udvikle og implementere finansielle strategier, styrke gennemsigtighed og forbedre organisationers rentabilitet. Christian har vist sig kompetent til at implementere skalerbare processer og systemer, der underst&#xf8;tter v&#xe6;kst og sikrer overensstemmelse med investorforventninger.&#xa0;
Samtidig v&#xe6;lger selskabet at udpege Sebastian Bo Jakobsen som CEO for Reponex Pharmaceuticals - PEG datterselskab. Udn&#xe6;vnelsen skal sikre et skarpere isoleret fokus p&#xe5; Reponex Pharmaceuticals A/S og s&#xe6;rligt selskabets kliniske udviklingsaktiviteter. Samtidig vil den organisatoriske opdeling muligg&#xf8;re en yderligere intensivering af arbejdet med etablering af strategiske samarbejder med potentielle licenspartnere.
Disclaimer: HC Andersen Capital modtager betaling fra Pharma Equity Group p&#xe5; en Digital IR/Corporate Visibility aftale./Claus Thestrup 03.03.2025 kl 08:10.